Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Eli Lilly and Company
University of Nebraska
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
Cellectar Biosciences, Inc.
M.D. Anderson Cancer Center
Servier
Jazz Pharmaceuticals
City of Hope Medical Center
Novartis
University of Alabama at Birmingham
Thomas Jefferson University
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Istari Oncology, Inc.
Washington University School of Medicine
University of Alabama at Birmingham
Deciphera Pharmaceuticals, LLC
Columbia University
Center Trials & Treatment Europe
Duke University
Biogen
Jonsson Comprehensive Cancer Center
Case Comprehensive Cancer Center
Lumos Pharma
Emory University
Medical College of Wisconsin
M.D. Anderson Cancer Center
Wake Forest University Health Sciences
Center Trials & Treatment
DNAtrix, Inc.
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
City of Hope Medical Center
City of Hope Medical Center
Masonic Cancer Center, University of Minnesota
City of Hope Medical Center
City of Hope Medical Center
Roswell Park Cancer Institute
University of Washington
Duke University
Duke University
Jonsson Comprehensive Cancer Center
National Cancer Institute (NCI)
Merck Sharp & Dohme LLC
Laboratorio Elea Phoenix S.A.
City of Hope Medical Center
National Cancer Institute (NCI)